Short Interest in Eterna Therapeutics Inc. (NASDAQ:ERNA) Declines By 5.4%

Eterna Therapeutics Inc. (NASDAQ:ERNA) saw a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 40,100 shares, a decrease of 5.4% from the March 31st total of 42,400 shares. Based on an average daily volume of 8,700 shares, the short-interest ratio is presently 4.6 days. Currently, 1.4% of the company’s stock are short sold.

Institutional Trading of Eterna Therapeutics

A number of hedge funds have recently modified their holdings of ERNA. Sippican Capital Advisors lifted its position in shares of Eterna Therapeutics by 30.1% during the 3rd quarter. Sippican Capital Advisors now owns 28,100 shares of the company’s stock worth $61,000 after buying an additional 6,499 shares during the period. Vanguard Group Inc. raised its position in Eterna Therapeutics by 30.6% in the 3rd quarter. Vanguard Group Inc. now owns 24,898 shares of the company’s stock valued at $54,000 after purchasing an additional 5,830 shares during the last quarter. Finally, Lake Street Advisors Group LLC bought a new position in Eterna Therapeutics in the 4th quarter valued at $933,000. Institutional investors own 70.55% of the company’s stock.

Eterna Therapeutics Stock Performance

Shares of NASDAQ ERNA opened at $1.78 on Thursday. The company has a debt-to-equity ratio of 3.03, a quick ratio of 1.46 and a current ratio of 1.46. The firm has a market cap of $9.63 million, a price-to-earnings ratio of -0.44 and a beta of 4.16. The business’s 50-day simple moving average is $2.08 and its 200-day simple moving average is $1.72. Eterna Therapeutics has a 52 week low of $0.84 and a 52 week high of $3.45.

Eterna Therapeutics (NASDAQ:ERNA) last released its earnings results on Thursday, March 14th. The company reported ($1.14) earnings per share (EPS) for the quarter. The business had revenue of $0.02 million during the quarter.

Eterna Therapeutics Company Profile

Eterna Therapeutics Inc operates as a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.